amikacin has been researched along with Empyema, Thoracic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SM; Chen, TT; Liu, HY | 1 |
| Matsumoto, T; Otsuka, K; Tomii, K | 1 |
2 other study(ies) available for amikacin and Empyema, Thoracic
| Article | Year |
|---|---|
Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema: A case report.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Drug Combinations; Empyema, Pleural; Female; Humans; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Mycobacterium fortuitum thoracic empyema: A case report and review of the literature.
Topics: Amikacin; Anti-Bacterial Agents; Chronic Disease; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Drug Combinations; Drug Therapy, Combination; Empyema, Pleural; Humans; Hypercapnia; Imipenem; Male; Middle Aged; Mycobacterium fortuitum; Noninvasive Ventilation; Sulfamethoxazole | 2015 |